On Oct. 13, 2020, the National Institute of Allergy and Infectious Diseases (NIAID), launched a study designed to determine whether certain approved therapies or investigational drugs in late-stage clinical development show promise against COVID-19 and merit advancement into larger clinical trials.

The ACTIV-5 Big Effect Trial planned to enroll adult volunteers hospitalized with COVID-19 at as many as 40 U.S sites, and was conducted in collaboration with the NIHﾒs public-private partnership Accelerating COVID-19 Therapeutic Innovations and Vaccines program.